RS59637B1 - Tretiranje nafld i nash - Google Patents
Tretiranje nafld i nashInfo
- Publication number
- RS59637B1 RS59637B1 RS20191583A RSP20191583A RS59637B1 RS 59637 B1 RS59637 B1 RS 59637B1 RS 20191583 A RS20191583 A RS 20191583A RS P20191583 A RSP20191583 A RS P20191583A RS 59637 B1 RS59637 B1 RS 59637B1
- Authority
- RS
- Serbia
- Prior art keywords
- nash
- nafld
- mbx
- compound
- liver
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461978335P | 2014-04-11 | 2014-04-11 | |
| EP15728222.9A EP3129018B1 (en) | 2014-04-11 | 2015-04-10 | Treatment of nafld and nash |
| PCT/US2015/025416 WO2015157697A1 (en) | 2014-04-11 | 2015-04-10 | Treatment of nafld and nash |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS59637B1 true RS59637B1 (sr) | 2020-01-31 |
Family
ID=53373532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20191583A RS59637B1 (sr) | 2014-04-11 | 2015-04-10 | Tretiranje nafld i nash |
Country Status (27)
| Country | Link |
|---|---|
| US (7) | US9381181B2 (https=) |
| EP (1) | EP3129018B1 (https=) |
| JP (1) | JP6865038B2 (https=) |
| KR (1) | KR102374499B1 (https=) |
| CN (1) | CN106163508A (https=) |
| AU (1) | AU2015243239B2 (https=) |
| BR (1) | BR112016023269A8 (https=) |
| CA (1) | CA2944139C (https=) |
| CL (1) | CL2016002517A1 (https=) |
| CY (1) | CY1122602T1 (https=) |
| DK (1) | DK3129018T3 (https=) |
| EA (1) | EA036704B1 (https=) |
| ES (1) | ES2764467T3 (https=) |
| HR (1) | HRP20192299T1 (https=) |
| IL (1) | IL248193B (https=) |
| LT (1) | LT3129018T (https=) |
| MX (1) | MX369921B (https=) |
| NZ (1) | NZ724740A (https=) |
| PH (1) | PH12016501978B1 (https=) |
| PL (1) | PL3129018T3 (https=) |
| PT (1) | PT3129018T (https=) |
| RS (1) | RS59637B1 (https=) |
| SG (1) | SG11201608077PA (https=) |
| SI (1) | SI3129018T1 (https=) |
| SM (1) | SMT202000019T1 (https=) |
| UA (1) | UA121208C2 (https=) |
| WO (1) | WO2015157697A1 (https=) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010028067A1 (en) | 2008-09-02 | 2010-03-11 | Amarin Corporation Plc | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| CA2740874C (en) * | 2008-10-17 | 2018-02-27 | Metabolex, Inc. | Use of ppar.gamma.agonists to reduce small dense ldl particles |
| SG175390A1 (en) | 2009-04-29 | 2011-12-29 | Amarin Corp Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| PT3278665T (pt) | 2009-04-29 | 2020-11-19 | Amarin Pharmaceuticals Ie Ltd | Composição farmacêutica estável e métodos de utilização das mesmas |
| CN106074486A (zh) | 2009-06-15 | 2016-11-09 | 阿马里纳药物爱尔兰有限公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法 |
| US20110071176A1 (en) | 2009-09-23 | 2011-03-24 | Amarin Pharma, Inc. | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ778131A (en) | 2010-11-29 | 2023-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| EP2775837A4 (en) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | METHODS OF TREATING HYPERTRIGLYCERIDEMIA |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| ES2891473T3 (es) | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
| EP4338805B1 (en) | 2012-06-29 | 2025-06-04 | Amarin Pharmaceuticals Ireland Limited | Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal myocardial infarction in a subject on statin therapy |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US9814733B2 (en) * | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| RS57970B1 (sr) | 2014-03-20 | 2019-01-31 | Cymabay Therapeutics Inc | Tretman intrahepatičkih holestatskih oboljenja |
| KR102374499B1 (ko) * | 2014-04-11 | 2022-03-14 | 사이머베이 쎄라퓨틱스, 인코퍼레이티드 | Nafld 및 nash 의 치료 |
| SG10201801654RA (en) | 2014-05-28 | 2018-04-27 | Childrens Hospital Med Ct | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| AU2015331848B2 (en) | 2014-10-17 | 2022-03-03 | Children's Hospital Medical Center, D/B/A Cincinnati Children's Hospital Medical Center | In vivo model of human small intestine using pluripotent stem cells and methods of making and using same |
| CA2980296A1 (en) * | 2015-03-26 | 2016-09-29 | T3D Therapeutics, Inc. | Methods of treating liver disease using indane acetic acid derivatives |
| ES2980790T3 (es) | 2015-04-28 | 2024-10-03 | Basf As | Acidos grasos estructuralmente mejorados que contienen azufre para su uso en el tratamiento de la esteatohepatitis no alcohólica |
| WO2017049157A1 (en) | 2015-09-18 | 2017-03-23 | Duke University | Methods and compositions for the treatment of steatosis-associated disorders |
| WO2017139708A1 (en) | 2016-02-10 | 2017-08-17 | Synlogic, Inc. | Bacteria engineered to treat nonalcoholic steatohepatitis (nash) |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US12053445B2 (en) | 2016-03-31 | 2024-08-06 | Genfit | Methods of treatment of cholestatic diseases |
| CN109415685B (zh) | 2016-05-05 | 2023-07-04 | 儿童医院医疗中心 | 用于体外制造胃底组织的方法和与其相关的组合物 |
| GB201614455D0 (en) | 2016-08-24 | 2016-10-05 | Univ Oxford Innovation Ltd | Biomarkers |
| EP4553082A3 (en) * | 2016-11-04 | 2025-08-20 | Children's Hospital Medical Center | Liver organoid compositions and methods of making and using same |
| US10493363B2 (en) * | 2016-11-09 | 2019-12-03 | Activision Publishing, Inc. | Reality-based video game elements |
| EP3548507A4 (en) | 2016-12-05 | 2020-07-15 | Children's Hospital Medical Center | COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF |
| JP7248586B2 (ja) | 2017-04-14 | 2023-03-29 | チルドレンズ ホスピタル メディカル センター | 複数ドナー幹細胞組成物およびそれを作製する方法 |
| US11000491B2 (en) | 2017-05-05 | 2021-05-11 | Hepanova, Inc. | Amino-aryl-benzamide compounds and methods of use thereof |
| WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| JP2020533339A (ja) | 2017-09-13 | 2020-11-19 | ノバルティス アーゲー | Ｆｘｒアゴニストを含む組合せ |
| EP3694603B1 (en) | 2017-10-10 | 2026-04-08 | Children's Hospital Medical Center | Esophageal tissue and/or organoid compositions and methods of making same |
| WO2019083070A1 (ko) * | 2017-10-27 | 2019-05-02 | 주식회사 삼양사 | 비알코올성 지방간 질환의 예방 또는 개선용 조성물 |
| IL308604B2 (en) | 2017-12-06 | 2025-08-01 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
| EP3727394A4 (en) | 2017-12-21 | 2021-09-08 | Children's Hospital Medical Center | DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| EP4678727A3 (en) | 2018-07-26 | 2026-03-11 | Children's Hospital Medical Center | Hepato-biliary-pancreatic tissues and methods of making same |
| CA3112026A1 (en) | 2018-09-12 | 2020-03-19 | Children's Hospital Medical Center | Organoid compositions for the production of hematopoietic stem cells and derivatives thereof |
| KR20210110890A (ko) | 2018-09-24 | 2021-09-09 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
| EP3880185A1 (en) * | 2018-11-16 | 2021-09-22 | CymaBay Therapeutics, Inc. | Combination treatment of nafld and nash |
| EP3880187A1 (en) | 2018-11-16 | 2021-09-22 | CymaBay Therapeutics, Inc. | Treatment of obesity and its complications |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| US12600943B2 (en) | 2019-02-01 | 2026-04-14 | The University Of Hong Kong | Innervated organoid compositions and methods of making same |
| US12497597B2 (en) | 2019-05-31 | 2025-12-16 | Children's Hospital Medical Center | Methods of generating and expanding hematopoietic stem cells |
| AU2020283048A1 (en) | 2019-05-31 | 2021-12-23 | Children's Hospital Medical Center | Shaped organoid compositions and methods of making same |
| AU2020336272A1 (en) | 2019-08-23 | 2022-04-14 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021050945A1 (en) | 2019-09-12 | 2021-03-18 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| US12427134B2 (en) | 2019-11-12 | 2025-09-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| WO2021097034A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases |
| US20210145774A1 (en) * | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Treatment of alcoholic liver disease |
| US20210379043A1 (en) * | 2020-05-13 | 2021-12-09 | Terns Pharmaceuticals, Inc. | Combination treatment of liver disorders |
| CN115884765A (zh) | 2020-08-26 | 2023-03-31 | 基恩菲特公司 | 用于治疗原发性胆汁性胆管炎的组合物和方法 |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| AU2022274304A1 (en) * | 2021-05-11 | 2023-10-26 | Genfit | Ppar-agonists for use in the treatment of liver failure |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7101993B1 (en) | 1990-01-11 | 2006-09-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides containing 2′-O-modified purines |
| US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US6166197A (en) | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
| WO1996027606A1 (en) | 1995-03-06 | 1996-09-12 | Isis Pharmaceuticals, Inc. | Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom |
| NZ331217A (en) | 1996-02-14 | 2000-02-28 | Novartis Ag | Sugar-modified gapped oligonucleotides for eliciting RNase H activity for strand cleavage in an opposing strand |
| US5883109A (en) | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
| US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
| US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| US7511131B2 (en) | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| WO2005042478A2 (en) | 2003-09-19 | 2005-05-12 | Janssen Pharmaceutica, N.V. | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| KR101494067B1 (ko) | 2004-03-05 | 2015-02-16 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법 |
| JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| WO2008091863A1 (en) | 2007-01-23 | 2008-07-31 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
| CA2740874C (en) | 2008-10-17 | 2018-02-27 | Metabolex, Inc. | Use of ppar.gamma.agonists to reduce small dense ldl particles |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| HK1224186A1 (zh) | 2013-11-20 | 2017-08-18 | Cymabay Therapeutics, Inc. | 纯阖家族型高胆固醇血症的治疗 |
| RS57970B1 (sr) | 2014-03-20 | 2019-01-31 | Cymabay Therapeutics Inc | Tretman intrahepatičkih holestatskih oboljenja |
| KR102374499B1 (ko) | 2014-04-11 | 2022-03-14 | 사이머베이 쎄라퓨틱스, 인코퍼레이티드 | Nafld 및 nash 의 치료 |
| EP3160458A1 (en) | 2014-06-26 | 2017-05-03 | Cymabay Therapeutics, Inc. | Treatment of severe hypertriglyceridemia |
-
2015
- 2015-04-10 KR KR1020167031356A patent/KR102374499B1/ko active Active
- 2015-04-10 CN CN201580018550.9A patent/CN106163508A/zh active Pending
- 2015-04-10 ES ES15728222T patent/ES2764467T3/es active Active
- 2015-04-10 DK DK15728222.9T patent/DK3129018T3/da active
- 2015-04-10 HR HRP20192299TT patent/HRP20192299T1/hr unknown
- 2015-04-10 PL PL15728222T patent/PL3129018T3/pl unknown
- 2015-04-10 AU AU2015243239A patent/AU2015243239B2/en active Active
- 2015-04-10 PT PT157282229T patent/PT3129018T/pt unknown
- 2015-04-10 LT LTEP15728222.9T patent/LT3129018T/lt unknown
- 2015-04-10 BR BR112016023269A patent/BR112016023269A8/pt not_active Application Discontinuation
- 2015-04-10 PH PH1/2016/501978A patent/PH12016501978B1/en unknown
- 2015-04-10 UA UAA201609927A patent/UA121208C2/uk unknown
- 2015-04-10 RS RS20191583A patent/RS59637B1/sr unknown
- 2015-04-10 US US14/684,100 patent/US9381181B2/en active Active
- 2015-04-10 SG SG11201608077PA patent/SG11201608077PA/en unknown
- 2015-04-10 JP JP2016561799A patent/JP6865038B2/ja active Active
- 2015-04-10 SI SI201531047T patent/SI3129018T1/sl unknown
- 2015-04-10 NZ NZ72474015A patent/NZ724740A/en unknown
- 2015-04-10 EA EA201692050A patent/EA036704B1/ru unknown
- 2015-04-10 WO PCT/US2015/025416 patent/WO2015157697A1/en not_active Ceased
- 2015-04-10 EP EP15728222.9A patent/EP3129018B1/en active Active
- 2015-04-10 MX MX2016013375A patent/MX369921B/es active IP Right Grant
- 2015-04-10 CA CA2944139A patent/CA2944139C/en active Active
- 2015-04-10 SM SM20200019T patent/SMT202000019T1/it unknown
-
2016
- 2016-06-02 US US15/171,910 patent/US9616039B2/en active Active
- 2016-10-04 CL CL2016002517A patent/CL2016002517A1/es unknown
- 2016-10-05 IL IL248193A patent/IL248193B/en active IP Right Grant
-
2017
- 2017-03-02 US US15/447,895 patent/US9962346B2/en active Active
-
2018
- 2018-04-03 US US15/943,936 patent/US10188620B2/en active Active
- 2018-12-17 US US16/222,379 patent/US10342770B2/en active Active
-
2019
- 2019-05-23 US US16/420,465 patent/US10722483B2/en active Active
- 2019-12-20 CY CY20191101347T patent/CY1122602T1/el unknown
-
2020
- 2020-06-19 US US16/906,296 patent/US11179359B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11179359B2 (en) | Treatment of NAFLD and NASH | |
| CA3118961A1 (en) | Combination treatment of nafld and nash | |
| JP6568577B2 (ja) | 肝内胆汁うっ滞症の治療 | |
| CA3118965A1 (en) | Treatment of obesity and its complications | |
| HK1228275B (en) | Treatment of nafld and nash | |
| HK1228275A1 (en) | Treatment of nafld and nash |